morning welcome techne earn conference call third quarter fiscal year time participant place listen mode call open question follow management prepare remark session please limit question follow would like turn call techne senior director investor relation corporate development senior director investor relation corporate development good morning thank join call morning chief executive officer chief financial officer techne begin briefly cover safe harbor statement comment make conference call consider forward look statement include belief expectation company future result potential impact pandemic operation financial result company fiscal year identify certain factor could cause company actual result differ materially project forward look statement make call company undertake update forward look statement result information future event development company file available company website within investor relation section call financial measure provide information pertinent ongoing business performance table reconcile measure comparable measure available company press release issue earlier morning techne corporation website techne turn call president chief executive officer good morning everyone thank join third quarter conference call read press release earlier morning please announce techne deliver another strong quarter fiscal year year organic growth accelerate quarter continue build momentum first half fiscal year growth best organic growth company deliver year year year year basis year growth broad base across segment geography penetration biopharma remain strong continue improvement academia drive year year sequential acceleration business growth product category also broad base accelerate sequentially continue leadership simple simple western cell gene therapy genomics platform year deliver record organic growth focus profitability achieve adjust operate margin quarter time hire support growth investment combine restrict travel benefit profitability however position high growth market high gross margin product strengthen conviction ability sustain operate margin future pursuant strategic plan dive deeper performance would like welcome techne reminder announce acquisition early march close transaction early portfolio lead genetic carrier screen oncology research product diagnostic complement legacy clinical control business molecular diagnostic control bring pipeline high value product accelerate penetration growth also bring deep diagnostic commercialization regulatory expertise leverage accelerate growth clinical platform across organization unlike many diagnostic company size already profitable anticipate business accretive techne line growth accretive diagnostics genomics segment operate margin time look forward give update progress come quarter performance growth platform start protein science segment growth accelerate organically quarter core proteomic research reagent portfolio another strong quarter research protein grow nearly antibody grow teen newest protein frequently research production give recent success grow interest base vaccine could sustainable growth driver product line forward meanwhile antibody business continue benefit custom antibody service business grow catalog protein approximately antibody variation enable scientific research also potential therapeutic application potential support recently announce license agreement clinical stage biopharmaceutical company develop engineer monoclonal antibody cytokine treatment cancer autoimmune disease evaluate third proprietary techne antibody therapeutic development pipeline agreement speak potential value vast protein antibody content build last plus year represent largely untapped potential revenue stream company leadership antibody also unnoticed industry techne system brand recently name winner side innovation award award celebrate innovative solution product help shape life science sector understand resilience innovation award reflect techne quick impactful response pandemic develop commercialize antibody support research test initiative represent fifth consecutive year techne antibody innovation effort recognize award proud antibody also continue make significant progress advance cell gene therapy initiative include protein business reminder protein ingredient cell gene therapy workflow provide nutrient grow genetically modify cell prior infuse back patient portfolio protein increase quarter customer leverage cytokine advance immune cell regenerative medicine therapy continue scale state production facility qualification complete production initial protein currently launch digital market campaign promote facility capacity capability market message resonate cell gene therapy industry final potential protein supply agreement biopharma customer continue grow also build momentum market awareness acceptance another component cell gene therapy workflow solution novel nonviral base gene delivery system announce sign license agreement therapeutic development therapeutic genomic engineer service business include solution gain traction customer develop cell gene therapy grow funnel biopharma company rely experience hard cell line deliver solution complex project techne reach cell gene therapy much broader best class protein technology biopharma company increasingly rely offer across techne portfolio include antibody medium supplement portfolio analytical tool include simple western simple instrument develop scale cell gene therapy manufacture capability unite business leader across company develop strategy product technology best position create synergistic solution maximize productivity customer proteomic analytical tool portion protein science segment strength experience recent quarter continue automate multiplex immunoassay solution simple stellar quarter revenue increase globally simple ability deliver high quality reproducible data picogram level sensitivity smaller footprint comparatively expensive offer continue drive awareness interest placement utilization platform increase simple adoption cell gene therapy customer broader biopharma industry leverage platform biomarker discovery immune cell characterization quality control process also help accelerate broader adoption expand simple immunoassay cartridge portfolio include nine cartridge format cartridge offer provide simple user increase flexibility number sample biomarker assay cartridge simple assay cartridge available format deliver four eight assay simultaneously expand portfolio cartridge offer provide user option better align assay panel throughput requirement study finally keep high demand simple solution second manufacture shift initial stage expand physical capacity meet forecast demand simple value proposition continue resonate customer need fully automate effective multiplexing solution similar stellar quarter fully automate western platform simple western year year growth accelerate approximately even rapid adoption simple western many quarter continue invest future platform expand addressable market example recently introduce latest number simple western family instrument call lower platform offer picogram level sensitivity ability perform sequential chemo assay within feature introduce higher instrument last year call academic customer increasingly adopt automate western platform alleviate induce limitation activity maximize productivity anticipate feature profile increase penetration technology customer segment finally biologics instrument provide protein purity information directly bioprocessing also standout quarter growth continue experience broad demand biopharma include several company vaccine various stage development commercialization continue interest company work cell gene therapy provide update diagnostics genomics portfolio organic revenue increase start update tissue pathology franchise organic revenue increase quarter multiplexing technology strong quarter significant traction cell gene therapy application represent currently available method understand single cell distribution information within context tissue histology information critical understand safety efficacy profile gene therapy result company many enable study also increasingly validation technology follow experiment single cell resolution spatial information provide solution support move discovery translational research remain early stage penetrate research clinical potential excite technology plenty room continue growth look ahead excite product family launch recently leverage technology expand addressable market techne high renovation technology employ prove double probe design signal application system enable rapid flexible probe development target enable digitalization target formalin paraffin embed tissue deliver benefit current commercial fish technique fall short detail nuclear stain rely high resolution microscopy visualize gene rearrangement copy number variation signal additionally traditional fish artificial back colon base probe large tend span multiple gene lack single gene detection specificity unlike commercially available assay utilize oligo probe couple proprietary signal amplification system enable high resolution precise target detection small genomic region single gene local diagnostics liquid biopsy platform start prostate cancer liquid biopsy assay prostate test urology practice largely reopen point older population primary audience prostate test remain hesitant visit doctor relate concern clearly headwind test volume since pandemic begin experience continue recovery prostate test volume march represent best month test sample inflow since begin pandemic encourage volume trajectory experience march anticipate continue momentum business vaccination continue work population patient return physician prostate test private payer increasingly recognize patient benefit save prostate deliver avoid unnecessary biopsy strong data support efficacy clinical utility test recognition lead contract coverage decision humana first national payer issue favorable coverage decision remain discussion several national regional payer look forward expand access test enable additional make inform decision whether defer proceed prostate biopsy also expand geographic reach prostate test complete clinical validation self enable certification march test perform clinical laboratory make available throughout various distribution channel begin addition prostate test continue advance pipeline novel base liquid biopsy product announce initial data next commercial test assay design detect kidney transplant rejection initial data support potential publish journal society assay capable discriminate rejection rejection negative predictive value positive predictive value view initial data best class compare compete kidney transplant rejection assay differentiate best class data test urine blood sample open opportunity home sample collection allow immuno patient ability take test comfort home avoid trip hospital blood draw look forward launch later calendar relate headwind restriction impact test volume patient defer routine business physician also impact broader diagnostic test volume despite ongoing challenge diagnostic reagent division increase single digit seventh quarter diagnostic reagent division deliver positive growth development pipeline relate opportunity continue smooth impact sometimes lumpy bulk reagent order like give update initiative since start pandemic techne reagent instrument enable insight virus include probe detect virus tissue sale bulk diagnostic reagent test application pathogen specific antibody protein know variance virus estimate tailwind business include initial revenue sale antibody serology expect research diagnostics around many year particularly viral strand continue emerge make tailwind sustain layer product portfolio forward business clearly fire innovative portfolio proteomic reagent research reagent analytical tool tissue biopsy spatial product meet productivity need scientific community drive research discovery forward emerge cell gene therapy workflow solution enable next class biological therapy increase efficiency lower liquid biopsy platform expand best class assay kidney transplant patient need better solution detect rejection layer favorable research fund environment believe techne best position ever least since company deliver long term revenue profitability aspiration keep bigger every year turn call chief financial provide overview fiscal financial performance total company provide additional detail performance segment give think remainder fiscal year start overall third quarter financial performance adjust versus year increase last year represent company record foreign exchange negatively impact quarter compare prior year represent increase year year revenue million increase year year report basis organic basis foreign exchange translation favorable impact revenue geography strong growth lead grow nearly follow growth growth north rest world grow teen recall last year start pandemic severely slightly lesser extent fiscal year business materially impact pandemic shutdown last year hence comp year easier revenue year still nearly higher quarter fiscal year revenue higher fiscal year revenue quarter fiscal year market biopharma continue strong year year growth academia continue make improvement grow approximately quarter compare last year move detail total company adjust gross margin quarter compare prior year increase primarily drive favorable product volume leverage adjust revenue basis point decrease compare prior year expense revenue basis point lower prior year adjust spend increase sequentially versus prior year tight labor market life science space allow fill plan headcount addition pace anticipate especially technical scientific engineer field however pace hire increase course still plan fill remain open position investment critical human capital position company growth forward result adjust operate margin increase basis point prior year basis point sequential improvement highest adjust operate margin company year look number operate income interest expense million decrease million compare prior year period decrease continue reduction bank debt fiscal lower float rate bank debt balance sheet stand million adjust operate expense million quarter compare million income prior year primarily reflect foreign exchange impact relate cash arrangement report operate income include unrealized loss investment move adjust effective rate basis point improvement prior year improvement primarily drive geographic expect effective rate forward consistent change corporate note effective rate favorably impact discrete time stock option exercise reminder make strategic equity investment base company focus provide medium custom cell line development medium formulation service biopharmaceutical market control interest line item reflect loss portion impact line result consolidate immaterial turn cash flow return capital million cash generate operation quarter increase prior year investment capital expenditure million return million capital shareholder million dividend million stock buyback finish million average dilute share outstanding balance sheet finish strong position million cash short term available sale investment essentially zero debt leverage position next performance report segment start protein science segment report sale million report revenue increase organic growth increase foreign exchange favorable impact revenue growth within segment strong growth broad base double digit growth nearly reagent assay instrument platform describe remark platform noble mention include simple simple western biologics cell gene therapy especially protein core proteomic reagent business operate margin protein science segment increase basis point year year primarily favorable volume leverage management turn diagnostics genomics segment report sale million report revenue increase organic growth segment foreign exchange translation favorable impact revenue similar first half fiscal year genomics division lead segment quarter experience strength across entire brand portfolio diagnostic partnership drive growth diagnostics revenue increase last year strong revenue companion diagnostic partnership drive growth prostate test continue recover pandemic experience fiscal last year mention diagnostics reagent division continue growth streak execute relate opportunity offset headwind many traditional diagnostic customer face patient forgo routine visit doctor move diagnostics genomics segment operate margin segment operate margin improve basis point compare prior year increase reflect strong volume leverage genomics division strong management across segment summary momentum experience first half fiscal accelerate organic revenue growth year date product remain forefront science enable edge scientific therapeutic discovery growth driver remain underpenetrated large grow market believe pandemic elevate profile market awareness tool solution offer position techne exit pandemic stronger pandemic bring think might close year short base business look strong similar line term absolute revenue bottom line term adjust customer biopharma academia back work need priority fund medical research still high private public sector strong revenue rate experience continue fuel support revenue growth fiscal year beyond critical catch growth investment strategic plan accomplish year already mention make good progress hire human capital need continue fully expect adjust operate margin finish sequentially lower still significantly higher prior year higher previous analyst consensus estimate also expect acquisition contribute sequentially revenue base business however recently become profitable likely dilutive overall adjust operate margin approximately basis point conclude prepare comment turn call open line question